Bioactive Heterocycles II pp 73-97

Part of the Topics in Heterocyclic Chemistry book series (TOPICS, volume 8)

Synthesis of Thalidomide

Abstract

Despite the most notorious medical disaster caused by thalidomide in medical history, huge numbers of papers have been published about this drug since its formulation in 1956. While most of the early studies specifically concerned teratogenicity, recently there has been a resurgence of interest in thalidomide because of its potential for treating a number of otherwise intractable diseases, such as leprosy, human immunodeficiency virus replication in acquired immune deficiency syndrome, and cancer. Although the pharmacological aspects of the drug have been frequently reviewed, reviews focusing on thalidomide synthesis are rare. Here, the synthesis of thalidomide is reviewed in chronological order from the first report. We first aim to give an overview of the most conventional aspects of thalidomide. Subsequently, we will focus on the synthesis of racemic thalidomide, which is now commercially available. Finally, we will describe the asymmetric synthesis of thalidomide. To our knowledge, all the papers and patents concerning thalidomide synthesis have been introduced. Because of the number of papers and patents, we will not mention the preparation of thalidomide derivatives.

Asymmetric synthesis Drug synthesis Teratogenicity Thalidomide  

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harousseau J-L (2006) Future Oncol 2:577 CrossRefGoogle Scholar
  2. 2.
    Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD (2006) Curr Drug Metab 7:677 CrossRefGoogle Scholar
  3. 3.
    Teo SK, Stirling DI, Zeldis JB (2005) Drug Discov Today 10:107 CrossRefGoogle Scholar
  4. 4.
    Frank ME, Macpherson GR, Figg WD (2004) Lancet 363:1802 CrossRefGoogle Scholar
  5. 5.
    Laffitte E, Revuz J (2004) Expert Opin Drug Saf 3:47 CrossRefGoogle Scholar
  6. 6.
    Botting J (2002) Drug News Perspect 15:604 CrossRefGoogle Scholar
  7. 7.
    Ng SSW, Brown M, Figg WD (2002) Biomed Pharmacother 56:194 CrossRefGoogle Scholar
  8. 8.
    Razza A (2002) Biochemist 24:21 Google Scholar
  9. 9.
    Hashimoto Y (2002) Bioorg Med Chem 10:461 CrossRefGoogle Scholar
  10. 10.
    Stirling D (2001) Semin Oncol 28:602 CrossRefGoogle Scholar
  11. 11.
    Jacobson JM (2000) Expert Opin Pharmacother 1:849 CrossRefGoogle Scholar
  12. 12.
    Franks ME, Marcpherson GR, Figg WD (2004) Lancet 363:1802 CrossRefGoogle Scholar
  13. 13.
    Waldman AR (2000) Clin J Oncol Nurs 4:99 Google Scholar
  14. 14.
    Stephens TD, Bunde CJ, Filmore BJ (2000) Biochem Pharmacol 59:1489 CrossRefGoogle Scholar
  15. 15.
    McBride WG (1961) Lancet 278:1358 CrossRefGoogle Scholar
  16. 16.
    Lenz W, Pfeiffer RA, Kosenow W, Hayman DJ (1962) Lancet 279:45 CrossRefGoogle Scholar
  17. 17.
    Sheskin J (1965) Clin Pharmacol Ther 6:303 Google Scholar
  18. 18.
    Chemie Grunenthal (1957) GB Patent 768821 Google Scholar
  19. 19.
    Ose S, Umemoto S (1960) JP Patent 35005071 Google Scholar
  20. 20.
    Ose S, Yoshimura Y, Saeki T (1960) JP Patent 35005277 Google Scholar
  21. 21.
    Muller GW (1997) US Patent 5698579 Google Scholar
  22. 22.
    Muller GW (1997) US Patent 5605914 Google Scholar
  23. 23.
    Muller GW, Konnecke WE, Smith AM, Khetani VD (1999) Org Process Res Dev 3:139 Google Scholar
  24. 24.
    Reepmeyer JC, Cox DC (1987) FDA monograph: guidelines to thalidomide synthesis. US Food & Drug Administration, Washington, DC Google Scholar
  25. 25.
    Caddick S (1995) Tetrahedron 51:10403 CrossRefGoogle Scholar
  26. 26.
    Perreux L, Loupy A (2001) Tetrahedron 57:9199 CrossRefGoogle Scholar
  27. 27.
    Lidstrom P, Tierney J, Wathey B, Westman J (2001) Tetrahedron 57:9225 CrossRefGoogle Scholar
  28. 28.
    Larhed M, Moberg C, Hallberg A (2002) Acc Chem Res 35:717 CrossRefGoogle Scholar
  29. 29.
    Kuhnert N (2002) Angew Chem Int Ed 41:1863 CrossRefGoogle Scholar
  30. 30.
    Blackwell HE (2003) Org Biomol Chem 1:1251 CrossRefGoogle Scholar
  31. 31.
    Kappe CO (2004) Angew Chem Int Ed 43:6250 CrossRefGoogle Scholar
  32. 32.
    Xu Y, Guo Q-X (2004) Heterocycles 63:903 CrossRefGoogle Scholar
  33. 33.
    Kirschning A, Solodenko W, Mennecke K (2006) Chem Eur J 12:5972 CrossRefGoogle Scholar
  34. 34.
    Seijas-Vazquez JA, Vazquez-Tato MP, Gonzalez-Bande C, Pacios-Lopez B (2003) ES Patent 2190707 Google Scholar
  35. 35.
    Seijas JA, Vazquez-Tato MP, Gonzalez-Bande C, Martinez MM, Pacios-Lopez B (2001) Synthesis 999 Google Scholar
  36. 36.
    Hijji YM, Benjamin E (2001) 5th International electronic conference on synthetic organic chemistry, 1–30 September 2001, p 1084 Google Scholar
  37. 37.
    Hijji YM, Benjamin E (2002) 6th International electronic conference on synthetic organic chemistry, 1–30 September 2002, p 1084 Google Scholar
  38. 38.
    Hijji YM, Benjamin E (2003) 7th International electronic conference on synthetic organic chemistry, 1–30 November 2003, p 1084 Google Scholar
  39. 39.
    Hijji YM, Benjamin E (2004) 8th International electronic conference on synthetic organic chemistry, 1–30 November 2004, p 1084 Google Scholar
  40. 40.
    Kassel DB (2001) Chem Rev 101:255 CrossRefGoogle Scholar
  41. 41.
    Amold FH (2001) Nature 409:253 CrossRefGoogle Scholar
  42. 42.
    Lehn J-M, Eliseev AV (2001) Science 291:2331 CrossRefGoogle Scholar
  43. 43.
    Schweizer F (2002) Angew Chem Int Ed 41:230 CrossRefGoogle Scholar
  44. 44.
    Brase S, Gil C, Knepper K (2002) Bioorg Med Chem 10:2415 CrossRefGoogle Scholar
  45. 45.
    Boger DL (2003) Bioorg Med Chem 11:1607 CrossRefGoogle Scholar
  46. 46.
    Brase S (2004) Acc Chem Res 37:805 CrossRefGoogle Scholar
  47. 47.
    Dolle RE (2004) J Comb Chem 6:623 CrossRefGoogle Scholar
  48. 48.
    Reymond J-L (2004) Angew Chem Int Ed 43:5577 CrossRefGoogle Scholar
  49. 49.
    Nefzi A, Ostresh JM, Yu J, Houghten RA (2004) J Org Chem 69:3603 CrossRefGoogle Scholar
  50. 50.
    Schwalbe T, Autze V, Hohmann M, Stimer W (2004) Org Process Res Dev 8:440 CrossRefGoogle Scholar
  51. 51.
    Spring DR (2005) Chem Soc Rev 34:472 CrossRefGoogle Scholar
  52. 52.
    Brown ED, Wright GD (2005) Chem Rev 105:759 CrossRefGoogle Scholar
  53. 53.
    Blotny G (2006) Tetrahedron 62:9507 CrossRefGoogle Scholar
  54. 54.
    Greco G, Novelino E, Martin YC (1998) Des Bioact Mol 219 Google Scholar
  55. 55.
    Vedani A, Dobler M (2000) Prog Drug Res 55:105 Google Scholar
  56. 56.
    Akamatsu M (2002) Curr Top Med Chem 2:1381 CrossRefGoogle Scholar
  57. 57.
    Mekenyan O (2002) Curr Pharm Des 8:1605 CrossRefGoogle Scholar
  58. 58.
    Schmieder P, Mekenyan O, Bradbury S, Veith G (2003) Pure Appl Chem 75:2389 CrossRefGoogle Scholar
  59. 59.
    Bultinck P, Winter HD, Langenaeker W, Tollenare J (eds) (2004) Computational Medicinal Chemistry for Drug Discovery, 1st edn. Marcel Dekker, New York Google Scholar
  60. 60.
    Debnath AK (2005) Curr Pharm Des 11:3091 CrossRefGoogle Scholar
  61. 61.
    Locuson CW, Wahlstrom JL (2005) Drug Metab Dispos 33:873 CrossRefGoogle Scholar
  62. 62.
    Allen DD, Geldenhuys WJ (2006) Life Sci 78:1029 CrossRefGoogle Scholar
  63. 63.
    Berger RD (2006) Drug Discov Today 11:429 CrossRefGoogle Scholar
  64. 64.
    Xiao Z, Schaefer K, Firestine S, Li P-K (2002) J Comb Chem 4:149 CrossRefGoogle Scholar
  65. 65.
    Chang M-Y, Chang C-H, Chen S-T, Chang N-C (2002) J Chin Chem Soc (Taipei) 49:383 Google Scholar
  66. 66.
    Chang M-Y, Lin K-G, Chen S-T, Chang N-C (2003) J Chin Chem Soc (Taipei) 50:795 Google Scholar
  67. 67.
    Chang M-Y, Chen S-T, Chang N-C (2003) Syn Commun 33:1375 CrossRefGoogle Scholar
  68. 68.
    Greig NH, Holloway H, Brossi A, Zhu X, Giordano T, Yu Q-S, Figg WD (2005) WO Patent 2005028436 Google Scholar
  69. 69.
    Gao L, Yuan X, Guo H, Liu X (2003) CN Patent 1405166 Google Scholar
  70. 70.
    Zhang H (2005) CN Patent 1597680 Google Scholar
  71. 71.
    Yuan X-H, Guo H-Q, Qiu X-P, Kang C-Q, Liu X-D, Gao L-X (2005) Gaodeng Xuexiao Huaxue Xuebao 26:1477 Google Scholar
  72. 72.
    Alpegiani M, Mazzoni A, Vergani D, Cabri W (2005) EP Patent 1602654 Google Scholar
  73. 73.
    Varala R, Adapa SR (2005) Org Proc Res Dev 9:853 CrossRefGoogle Scholar
  74. 74.
    Blaschke G, Kraft HP, Fickentscher K, Kohler F (1979) Arzneimittelforschung 29:1640 Google Scholar
  75. 75.
    Winter W, Frankus E (1992) Lancet 339:365 CrossRefGoogle Scholar
  76. 76.
    Blaschke G, Knoche B (1994) J Chromatogr 2:183 Google Scholar
  77. 77.
    Nishimura K, Hashimoto Y, Iwasaki S (1994) Chem Pharm Bull 42:1157 Google Scholar
  78. 78.
    Wnendt S, Finkam M, Winter W, Ossing J, Rabbe G, Zwingenberger K (1996) Chirality 8:390 CrossRefGoogle Scholar
  79. 79.
    Sampaio EP, Sarno EN, Gallily R, Cohn ZA, Kaplan G (1991) J Exp Med 173:699 CrossRefGoogle Scholar
  80. 80.
    Meyring M, Mühlbacher J, Messer K, Kastner-Pustet N, Bringmann G, Mannschreck A, Blaschke G (2002) Anal Chem 74:3726 CrossRefGoogle Scholar
  81. 81.
    De Camp WH (1989) Chirality 1:2 CrossRefGoogle Scholar
  82. 82.
    Ed. Chirality (1990) Lancet 336:1100 Google Scholar
  83. 83.
    Lien EJ (1995) J Drug Target 2:527 CrossRefGoogle Scholar
  84. 84.
    Wnendt S, Zwingenberger Z (1997) Nature 385:303 CrossRefGoogle Scholar
  85. 85.
    Casini G, Ferappi M (1964) Farmaco Ed Sci 19:563 Google Scholar
  86. 86.
    Shealy YF, Opliger CE, Montgomery JA (1965) Chem Ind 1030 Google Scholar
  87. 87.
    Shealy YF, Opliger CE, Montgomery JA (1968) J Pharm Sci 57:757 CrossRefGoogle Scholar
  88. 88.
    Blaschke G, Kraft HP, Fickentscher K, Kohler F (1979) Arzneimittelforschung 29:1640 Google Scholar
  89. 89.
    Blaschke G, Kraft HP, Markgraf H (1980) Chem Ber 113:2318 CrossRefGoogle Scholar
  90. 90.
    Francotte E, Wolf RM (1992) J Chromatogr 595:63 CrossRefGoogle Scholar
  91. 91.
    Reepmeyer JC (1996) Chirality 8:11 CrossRefGoogle Scholar
  92. 92.
    Chankvetadz B, Schulte G, Blaschke G (1997) J Pharm Biomed Anal 15:1577 CrossRefGoogle Scholar
  93. 93.
    Meyring M, Chankvetadze B, Blaschke G (2000) J Chromatogr A 876:157 CrossRefGoogle Scholar
  94. 94.
    Meyring M, Muhlenbrock C, Blaschke G (2000) Electrophoresis 21:3270 CrossRefGoogle Scholar
  95. 95.
    Zhang Y, Watts W, Nogle L, McConnell O (2004) J Chromatogr A 1049:75 CrossRefGoogle Scholar
  96. 96.
    Murphy-Poulton SF, Boyle F, Gu XQ, Mather LE (2006) J Chromatogr B 831:48 CrossRefGoogle Scholar
  97. 97.
    Robin S, Zhu J, Galons H, Pham-Huy C, Claude JR, Tomas A, Viossat B (1995) Tetrahedron Asymmetry 6:1249 CrossRefGoogle Scholar
  98. 98.
    Flaih N, Pham-Huy C, Galons H (1999) Tetrahedron Lett 40:3697 CrossRefGoogle Scholar
  99. 99.
    Suzuki E, Shibata N (2001) Enantiomer 6:275 Google Scholar
  100. 100.
    Iong J, Shibata N, Toru T (2005) JP Patent 2005336157 Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  1. 1.Graduate School of EngineeringNagoya Institute of TechnologyNagoyaJapan

Personalised recommendations